Immersion

Does psilocybin therapy help with depression?

Short answer

Early research says yes, with real promise and real limits. Small trials of psilocybin-assisted therapy found large drops in depression, lasting up to a year for some people. A larger, more rigorous trial found a smaller benefit that was less clearly lasting. It is still investigational, studied only in supervised settings.

The research
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., and Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, volume 78, issue 5, pages 481 to 489.
Sample 24 adults with major depression who completed two supervised psilocybin sessions paired with supportive therapy
Published 2021
Journal JAMA Psychiatry
Alan Davis and colleagues at Johns Hopkins ran a small randomized trial of psilocybin-assisted therapy for major depression. They enrolled 27 adults and compared starting treatment right away with waiting about eight weeks first. Twenty-four people completed the program, which paired two supervised psilocybin sessions with around eleven hours of talking therapy before, between, and after. Depression was measured with a standard clinician-rated scale, the GRID-Hamilton Depression Rating Scale, where a higher score means more severe depression. The group that started right away improved far more than the group still waiting. Their average score fell from the severe range, about 23, down to around 8 at both one week and four weeks after treatment, while the waiting group stayed high. By the usual statistical measure the gap between the groups was very large. At four weeks, 71 percent of people had responded, meaning their depression had at least halved, and 54 percent were in remission, meaning their symptoms had mostly cleared. The authors were careful about what this shows. It was a small, early trial run in a supervised research setting, not evidence that the treatment works for everyone or outside that kind of setting.
Read the paper

What does this mean for you?

Here is the plain version. In a handful of carefully run trials, psilocybin given alongside real psychological support was linked to big improvements in depression, and in the Johns Hopkins group those gains were still there a year later for most of the people who had responded. That is a striking result for a condition that is often stubborn. It is also why the research has drawn so much attention.

But the honest picture is more mixed than the headlines. The Hopkins trial was small, only two dozen people, and everyone knew they had received an active drug, which can shape how people report feeling. When a much larger and more rigorous trial of 233 people with harder-to-treat depression put a single psilocybin session up against a very low comparison session, it still found a real benefit at three weeks, but a smaller one, and the evidence that the improvement lasted out to twelve weeks was not clear. Uncomfortable reactions during and after sessions were common.

So the fair reading is this. The early signal is genuine and worth taking seriously, and it is not a finished story. The benefit in the small trials looks larger than what the bigger trial found, durability is still an open question, and none of this happened at home. In every one of these studies the drug was only one part. It came wrapped in preparation, a supervised session, and hours of integration afterward, which is the slow work of making sense of what came up.

This matters for how you hold the question. Psilocybin therapy is still investigational. It is not an approved, walk-in treatment, and these results come from supervised research with trained teams, not from people trying it on their own. The thing being tested is the whole process, not a substance by itself.

The takeaway

Terms in this page
Set and setting Integration Window of neuroplasticity

This is the work Asendar™ was built for: the preparation that steadies you before a session and the integration that carries what surfaced into the days after, which is where much of the lasting change in this research actually happened. If you want a simple read on where your head is today, take your Mental Readiness Score.

Take your Mental Readiness Score

People also ask

Do the effects of psilocybin therapy last?

In the small Johns Hopkins group, a 12-month follow-up found the improvements largely held: about 75 percent had responded and 58 percent were in remission a year later, with no serious related harms in that window. That is encouraging, but it is a small sample, and a larger trial was less clear that the benefit lasted. Durability is still an open question.

Is psilocybin therapy better than regular depression treatment?

The research does not show that yet. Most trials compared psilocybin-assisted therapy with waiting or with a very low comparison session, not head to head against established treatments over the long run. The early signal is strong, but it is early, and the honest answer is that we do not yet know how it stacks up against standard care.

Can I try psilocybin therapy for my depression now?

It is still investigational, studied in supervised clinical settings with trained teams, not available as a walk-in treatment. These results do not describe people using it on their own. If you are curious, the useful next step is an honest conversation with your own care team about where the evidence stands and what is right for you.

Explore more in the Immersion pillar